NANETS/SNMMI consensus statement on patient selection and appropriate use of 177Lu-DOTATATE peptide receptor radionuclide therapy

Thomas A. Hope, Lisa Bodei, Jennifer A. Chan, Ghassan El-Haddad, Nicholas Fidelman, Pamela L. Kunz, Josh Mailman, Yusuf Menda, David C. Metz, Erik S. Mittra, Daniel A. Pryma, Diane L. Reidy-Lagunes, Simron Singh, Jonathan R. Strosberg

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


With the growing use of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT), there are many unanswered questions regarding patient selection. In this document, we review the literature on the use of 177Lu-DOTATATE in neuroendocrine tumors (NETs) of different primary origin, discuss issues of controversy, and review potential contraindications to treatment. The present consensus statement was developed collaboratively by the North American Neuroendocrine Tumor Society (NANETS) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). NANETS is a multidisciplinary professional society of neuroendocrine specialists in North America that was founded in 2005. NANETS’ mission is to improve NET disease management through increased research and educational opportunities. NANETS is committed to a multidisciplinary approach and consists of doctors and scientists involved in different specialties of NETs. SNMMI is an international scientific and professional organization founded in 1954 to promote the science, technology and practical application of nuclear medicine. In addition to publishing journals, newsletters, and books, the SNMMI also sponsors international meetings and workshops designed to increase the competencies of nuclear medicine practitioners and to promote new advances in the science of nuclear medicine.

Original languageEnglish (US)
Pages (from-to)222-227
Number of pages6
JournalJournal of Nuclear Medicine
Issue number2
StatePublished - Feb 2020

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'NANETS/SNMMI consensus statement on patient selection and appropriate use of <sup>177</sup>Lu-DOTATATE peptide receptor radionuclide therapy'. Together they form a unique fingerprint.

Cite this